

Supplemental Information

**Hepatitis Delta Virus Acts as an Immunogenic
Adjuvant in Hepatitis B Virus-Infected Hepatocytes**

Christine Y.L. Tham, Janine Kah, Anthony T. Tan, Tassilo Volz, Adeline Chia, Katja Giersch, Yvonne Ladiges, Alessandro Loglio, Marta Borghi, Camille Sureau, Pietro Lampertico, Marc Lütgehetmann, Maura Dandri, and Antonio Bertoletti

NTCP




Figure S1: Expression of HDV RNA in HepG2-hNTCP cells quantified by PrimeFlow RNA Assay, related to Fig 1. A representative dot plot of the uninfected, HBV mono-infected and HBV/HDV infected cells are shown.


NTCP

Figure S2: Expression of immune genes in HepG2-hNTCP cells, related to Fig 2. Normalized counts of nanostring probes corresponding to co-inhibitory molecules, co-stimulatory molecules, antigen presentation (HLA-A, -B, -C and B2M) and antigen processing (PSMB-8, -9, TAP-1 and -2) were depicted in infected HepG2-hNTCP cells. Bars represent the mean normalized count and each dot depicts a single experiment (n=2).




Figure S3: Titration of IFN- α , IFN- β and IFN- λ for 24 and 48 hour duration to determine the amount of IFNs to use for maximal surface expression of MHC class I complexes, related to Fig 4. HepG2-hNTCP and HepG2.2.15 cells were treated for either 24 or 48 hours in the respective IFN doses and stained with anti-MHC class I antibodies to determine the surface expression of IFN-induced MHC Class I complexes.